Differential diagnostic capabilities of calculating the level of neutrophil extracellular traps in the venous blood of pregnant women: a comparative prospective study


N.B. Kuzina, E.N. Plakhotina, A.N. Kuzovlev1  , T.N. Belousova, E.V. Bryantsev, D.V. Kasina

1 Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia

2 Vidnovsky perinatal center, Vidnoye, Russia

3 Moscow Regional Research and Clinical Institute, Moscow, Russia

For correspondence: Artem N. Kuzovlev, MD, PhD, head of the V. Negovsky research institute of general reanimatology, head of the chair of Anesthesiology and Resuscitation, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia; e-mail: artem_kuzovlev@mail.ru

For citation: Kuzina N.B., Plakhotina E.N., Kuzovlev A.N., Belousova T.N., Bryantsev E.V., Kasina D.V. Differential diagnostic capabilities of calculating the level of neutrophil extracellular traps in the venous blood of pregnant women: a comparative prospective study. Annals of Critical Care. 2021;4:79–87. DOI: 10.21320/1818-474X-2021-4-79-87


Introduction. Severe preeclampsia in early stages can be detected by isolated thrombocytopenia, which makes it difficult to diagnose it in time and carry out the necessary therapeutic measures. As a rule, the diagnosis of severe preeclampsia can be declared with a detailed clinical and laboratory researches, and it increases the risks for the mother and the embryo. However, if there are no clinical symptoms of preeclampsia except of thrombocytopenia, there is a problem of differential diagnosis between thrombocytopenia, which has the same symptoms as preeclampsia and gestational thrombocytopenia, which is a physiological peculiarity and does not require any medical interventions and restrictions. Nowadays there are no screening methods for differential diagnosis of these conditions. Objectives. To estimate the possibilities of determing the level of neutrophil extracellular traps (NETs) during the differential diagnosis of preeclampsia and gestational thrombocytopenia. Materials and methods. The comparative analysis of the level of NETs was carried out in three groups of pregnant women. Group 1 included patients with severe preeclampsia (n = 45), group 2-patients with gestational thrombocytopenia (n = 44) and group 3 consisted of healthy pregnant women (n = 44). Results. The research revealed significant increase in the level of NETs in the group of patients with preeclampsia (15.26 %,) compared with the groups of healthy patients (7.65 %, p = 0.001) and patients with gestational thrombocytopenia (7.04 %, р = 0.002). There were no significant differences in the level of NETs between the groups of healthy patients and patients with gestational thrombocytopenia. Conclusions. A significant increase of the level of NETs among the patients with severe preeclampsia allows us to consider the method of calculating the level of NETs among patients with thrombocytopenia which can be detected after the 20th week of pregnancy, if there are no other laboratory and clinical signs of preeclampsia as a screening method for early diagnosis of this complication.

Keywords: pregnancy, pre-eclampsia, thrombocytopenia, neutrophil extracellular traps

Received: 04.10.2021

Accepted: 30.11.2021

Published online: 19.01.2022

Read in PDF

Лицензия Creative Commons Статистика Plumx английский


In 2004, A. Zychlinsky et al. described the phenomenon of neutrophils neutralizing pathogenic microorganisms through extracellular structures called “neutrophil extracellular traps” (NETs). Since the neutrophil dies during the formation of the traps, the mechanism of their production was named NETosis, similar to apoptosis and necrosis [1].

According to a literature report, percentage of NETs in healthy donors was 5.7±2.5% (Min-Max: 1.8% – 11.9%) [2].

Many studies show that the NET formation plays an important role in the pathogenesis of systemic lupus erythematosus [3], preeclampsia [4, 5], sepsis [6–8], cystic fibrosis [9], immunocomplex diseases [10], inflammatory bowel disease [11], atherosclerosis [12], antiphospholipid syndrome [13, 14].

In preeclampsia, reduced placental perfusion is associated, among others, with an increased release of inflammatory membrane microparticles of syncytiotrophoblast microvilli and cytokines in response to primary hypoxia caused by initially impaired trophoblast invasion. Increased blood levels of syncytiotrophoblast microvilli have been found in patients with preeclampsia. Studies have shown that syncytiotrophoblast microvilli destroy endothelium and inhibit endothelial cell proliferation in culture as well as endothelium-dependent relaxation of small arteries in vitro [15–18]. Inadequate placental perfusion in preeclampsia has been suggested to produce reactive oxygen species, which are inducers of NETosis. As a consequence, a vicious circle develops where initial hypoxia caused by malformation of spiral arteries and related oxidative stress induces neutrophils to form traps, which aggravate abnormal placental blood flow by increasing hypoxia and oxidative stress [5, 19–23].

Severe pre-eclampsia is characterized by rapid progression of clinical manifestations and such complications as intrauterine fetal growth delay (8–20%) [24], premature placental detachment [25], eclampsia (8%) [26], HELLP syndrome (4–12%) [27]. This complication ranks fourth among the causes of maternal mortality [24]. Preeclampsia results in over 70,000 maternal and 500,000 intrauterine/neonatal deaths annually worldwide [28]. When severe preeclampsia manifests as isolated thrombocytopenia, timely diagnosis and ruling out other types of thrombocytopenia, especially very common gestational one, are necessary.

Currently, the diagnosis of severe preeclampsia is made based on typical clinical and laboratory presentations. However, an atypical manifestation of the disease can reduce the awareness of preeclampsia, prompting the physician to diagnose gestational thrombocytopenia. This approach can lead to inappropriate patient management and result in major complications of preeclampsia. It is difficult to confirm or rule out pre-eclampsia in its early stages without a typical clinical presentation, even if the clinician is alert.  Diagnostic markers of early pre-eclampsia, such as the sflt-1/plgf ratio, are not readily available in routine clinical practice [29]. Overdiagnosis of this complication entails unwarranted polypharmacy and interventions, including premature delivery, which are not necessary in gestational thrombocytopenia. On the other hand, there are currently no strict diagnostic criteria for gestational thrombocytopenia and this diagnosis is usually made after ruling out the other possible conditions. Gestational thrombocytopenia is physiological in nature and usually does not associate with coagulation disorders nor requires any intervention and subsides after delivery [30,31]. 

Thus, there is currently no available screening method for differential diagnosis of early severe preeclampsia and other conditions associated with thrombocytopenia, including gestational one.

The objective of the study was to evaluate the value of NETs assessment in the differential diagnosis between preeclampsia and gestational thrombocytopenia.

Materials and methods

This comparative prospective clinical study of the venous blood levels of NETs in patients with severe preeclampsia, gestational thrombocytopenia, and healthy pregnant women was performed at the Vidnoye Perinatal Center (Fig. 1). The patients were assigned to 3 study groups. The sample size was estimated using the relevant determination tables [32].

Patients were recruited without randomization until the predefined number was reached.  Patients were allocated into groups after the diagnoses of severe preeclampsia and gestational thrombocytopenia had been confirmed or ruled out. Group 1 included 45 patients diagnosed with severe pre-eclampsia using the following criteria: diastolic BP greater than or equal to 110 mm Hg, systolic BP greater than or equal to 160 mm Hg, daily proteinuria greater than 5 g/L, and/or one or more additional criteria for severe preeclampsia (HELLP syndrome, persistent headaches, vomiting, other cerebral or visual disturbances, renal dysfunction, acute lung injury, pulmonary edema, optic edema, liver dysfunction, epigastric/right upper quadrant pain, thrombocytopenia and/or its progression, sudden-onset/progressive edema, evidence of fetal distress) [33]. Group 2 included 44 patients diagnosed with gestational thrombocytopenia using the following criteria: platelet count reduction during current pregnancy below 150 ´ 109/L, no diagnosis of thrombocytopenia of any origin prior to the current pregnancy [34].  Group 3 (the controls) consisted of 44 patients without preeclampsia or thrombocytopenia. Exclusion criteria common for all groups included conditions that, according to published data, may be associated with elevated NETs such as history of neoplastic disease or current diagnosis of neoplastic disease, a history of syphilis or current diagnosis of syphilis, hereditary thrombophilia (factor V, or Leiden, mutation, prothrombin gene mutation, dysfibrinogenemia, protein C and S gene mutation) diagnosed using genetic screening methods prior to the current pregnancy (if the patient had not been previously diagnosed with this condition and had not been tested for it, she was considered free of it), active chronic infectious disease, antiphospholipid syndrome diagnosed before an current pregnancy, based on the 2006 Australian Criteria (if the patient had not been previously diagnosed with this condition and had not been tested for it, she was considered free of it), systemic lupus erythematosus, cystic fibrosis, sepsis, rheumatoid arthritis, hemorrhagic vasculitis [3, 6–14]. Patients with Rh-negative blood, multiple gestation pregnancy, and gestational diabetes mellitus requiring insulin therapy were also excluded from the study. Analysis of the data obtained in this category of patients revealed a significant increase in the level of NETs, which requires further study (Fig. 1).

Figure 1. Flow chart of comparative prospective clinical study on the measurement and comparison of the NET level in the venous blood of patients with severe preeclampsia, gestational thrombocytopenia and healthy pregnant women


In order to quantify the level of NETs, the venous blood was collected from patients in the II–III trimesters of pregnancy in RusTech and PUTH general blood test tubes with EDTA. Later, a blood smear with a dense monolayer of cells was made within 1.5 hours of the sampling and examined according to the technique described in Russian patent No. 2121297 “Method for determining the percentage of NETotic phagocytes” using a smear making device (Medtekhnopark LLC). The method consists in sliding the edge of the top slide on the working surface of the bottom slide to produce a uniform blood smear one layer of red blood cells thick with the red blood cell density of 4-15 thousand per mm. For this purpose, 2 µl of sampled blood was used, the smears obtained were stained using Giemsa stain. Quantification of NETs generated by NETotic blood phagocytes was performed using the MECOS-C2 automated microscopy complex (MECOS CJSC) and synthetic immersion oil (Minimed LLC).

In all prepared smears, the native phagocyte count (Cnat) and destroyed altered phagocyte count (Cdestr), considered as NET marker, were calculated. The level of NETs was calculated according to the following formula:

NETs level = Cdestr/(Cnat-Cdestr) (%)

All analyzed data were checked for normality of distribution. In normal distribution, parametric criteria were used for description such as mean and standard deviation. Analysis of variance and Student’s t-criterion were used for comparative analysis of the studied groups in this case. If data distribution was non-normal, the results were presented as median (M) and 1st and 3rd quartiles (Q1-Q3) and Kruskal-Wallace and Mann-Whitney U-tests were used for comparative analysis. Pearson’s χ2 test was used to analyze the qualitative data. Differences were considered significant at P value <0.05. Statistical analysis was done using Statistica 10 software (StatSoft Inc., USA).

This study was approved by the ethical committee of the V.A. Negovsky Research Institute of General Reanimatology, Moscow (protocol no. 2/20/3, dated June 10, 2020).


When analyzing the age and body measurements (Table 1), no differences were found between the studied groups. The gestational age of studied patients (Table 1) was significantly lower in group 1 than in group 2 (p=0.000001, Mann-Whitney U-criterion) and in group 3 (p=0.0002, Mann-Whitney U-criterion). This difference can be explained by the frequent need for premature delivery in patients with severe preeclampsia. No differences in gestational age were found in groups 2 and 3 (Mann-Whitney U-criterion p>0.05). The higher incidence of preeclampsia in first-pregnant women [35,36,37] explains the prevalence of first-pregnant patients in group 1 compared with group 2 (p=0.006, Mann-Whitney U-criterion) and Group 3 (p=0.006, Mann-Whitney U-criterion) (Table 1). There were no significant differences between groups 2 and 3 (Mann-Whitney U-criterion, p>0.05).

Table 1. Characteristics of the studied groups


Group 1

Group 2

Group 3

Age, years

31 (23–37)

30 (27–31.5)

31 (25–35)

Body mass index, kg/m2

30.2 (25.4–35.9)

27.9 (25.6–29.5)

28.3 (26.3–29.6)

Gestation period, weeks

36.3 (30–38)*

39 (37.5–39.2)

39 (38–39.6)


1 (1–2)*

2 (1–2.25)

2 (1–2.75)

Note. The data are given as Me (Q1-Q3).

* p < 0.05 vs the other groups, Mann-Whitney U-criterion.


Most common comorbidities in the study participants included genitourinary and endocrine disorders (including overweight and obesity), and mild anemia. Prevalence of endocrine diseases, overweight and obesity in group 1, which accounted for 40.3% of the total comorbidity, is consistent with the published data on increased risk of preeclampsia in patients with these conditions [35–,37] (Table 2).

Table 2. Comorbidities and their frequencies in the studied groups


Group 1 n = 45

Group 2 n = 44

Group 3 n = 44

Р-value (c2-test)

Mild anemia

6 (9%)

8 (25.8%)

6 (15%)

р < 0.001

Large varicose veins

8 (11.9 %)

3 (9.7%)

3 (7.5%)

Gastrointestinal diseases

3 (4.5%)


3 (7.5%)

Musculoskeletal diseases




Cardiovascular diseases

6 (9%)

1 (3,3%)

6 (15%)

Respiratory diseases

2 (2.9%)



Endocrine diseases, overweight and obesity


7 (22.5%)

5 (12.5%)

Neurological diseases

3 (4.5%)


2 (5%)

Genitourinary diseases

12 (17.9%)

5 (16.2%)

11 (27.5%)


The differences in the number of patients in the groups and comorbidities were due to several concomitant diseases in some patients.

Thus, the intergroup differences in specific comorbidities and their frequencies are due to high incidence of endocrine diseases and overweight/obesity.  According to current concepts, overweight and obesity, while being risk factors for preeclampsia, do not play a significant role in the pathogenesis of this pregnancy complication and could not affect the results of this study [35,36,37].

The levels of NETs in the study groups are shown in Table 3.

Table 3. NET levels in the study groups





Standard deviation

Group 1 (n = 45), %





Group 2 (n = 44), %





Group 3 (n = 44), %





* p < 0.05 (Student’s t-test) vs groups 2 and 3.


The analysis of variance revealed significant intergroup differences in NETs levels (p = 0.003). In a pairwise comparison of groups using Student’s t-criterion, group 1 (patients with preeclampsia) had significantly higher NETs than group 2 (gestational thrombocytopenia) (p = 0.002). Comparison of the preeclampsia group values with those of healthy pregnant women (group 3) also revealed significant differences (p = 0.001). The levels of NETs did not differ between groups 2 and 3 (p > 0.05, Student’s t-test).


Due to lack of generally accepted reference values of the NETs level in the venous blood of pregnant women, the mean value of group 3 NETosis percentage was taken as reference and was 4.45-10.85% (7.65±3.2%, Min-Max: 1% to 13.7%).

The increase in NETs in preeclampsia found in this study is in accordance with previously published data. Similar results were obtained by A.K. Gupta et al. who showed that both microvilli of syncytiotrophoblast and soluble placental factors in vitro activate neutrophils to generate NETs. They also revealed that the traps were capable of ensnaring not only large objects, such as bacteria (>2 μm), but also very small (<200 nm) particles, such as microvilli of syncytiotrophoblast. In preeclampsia, the number of NETs in the placenta was significantly higher than in the placenta of healthy pregnant women [20].

Epithelial and endothelial dysfunction in preeclampsia may also be associated with increased levels of NETs, as shown by M. Saffarzadeh et al. who demonstrated a direct toxic effect of NET components on endothelium [38].

The procoagulant effect of traps, proven by many authors [39, 40], explains the occurrence of thrombocytopenia in preeclampsia, which primarily appears as consumption thrombocytopenia and may precede the overt clinical and laboratory manifestation of preeclampsia.

On the other hand, the absence of differences in NETs levels between the patients with gestational thrombocytopenia and women of the control group once again indicate the possible physiological nature of the former, also characterized by lack of severe endothelial damage and absent massive consumption thrombocytopenia in contrast to preeclamptic thrombocytopenia.

However, the limited knowledge on this issue warrants larger-scale studies to determine the reference values of the NETs levels in healthy pregnant women in relation to gestational age and compare them with the ones of non-pregnant healthy subjects.


  1. The comparative analysis revealed no differences in the levels of NETs in healthy pregnant women and patients with gestational thrombocytopenia which could indicate the physiological nature of the latter.
  2. A significant increase in the level of NETs in preeclampsia requires further study of the feasibility of using NETs assessment for early diagnosis of this complication in high-risk patients
  3. Significant differences in the level of NETs between patients with pre-eclampsia and those with gestational thrombocytopenia suggest using the studied method for the differential diagnosis of these conditions.

Disclosure. The authors declare that they have no competing interests.

Author contribution. Kuzina N.B., Plakhotina E.N., Kuzovlev A.N., Belousova T.N., Bryantsev E.V., Kasina D.V. — all authors according to the ICMJE criteria participated in the development of the concept of the article, obtaining and analyzing factual data, writing and editing the text of the article, checking and approving the text of the article.

Authors’ ORCID

Kuzina N.B. 

Plakhotina E.N. 

Kuzovlev A.N. 

Belousova T.N. 

Bryantsev E.V. 

Kasina D.V. 


  1. Brinkmann V., Reichard U., Goosmann C., et al. Neutrophil extracellular traps kill bacteria. Science (New York, N.Y.). 2004; (303)5663: 1532–5. DOI: 10.1126/science.1092385
  2. Mosalskaya D.V., Guryev A.S., Lopatin A.F. Prognostic value of determining the level of DNA traps in sepsis. Materials of the Conference: Sepsis 2018. 2018, 1–3 October. Bangkok, Thailand.
  3. Handono К., Pradana B.A., Nugroho R.A., et al. 1,25(OH)2D3 Inhibits Endothelial Apoptosis by Neutrophil Extracellular Traps Externalization in Systemic Lupus Erythematosus Patients. Turk J Immunol. 2017; 5(3): 89–95. DOI: 10.25002/tji.2017.623
  4. Marder W., Knight J.S., Kaplan M.J., et al. Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies. Lupus Sci Med. 2016; 3: e000134. DOI: 10.1136/lupus-2015-000134
  5. Gupta A.K., Hasler P., Holzgreve W., et al. Neutrophil NETs: a novel contributor to preeclampsia-associated placental hypoxia? Semin Immunopathol. 2007; 29: 163–7. DOI: 10.1007/s00281-007-0073-4
  6. Liu X., Shen Y., Wang H., et al. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Sepsis: A Prospective Observational Study. Mediators Inflamm. 2016; 2016: 8191254. DOI: 10.1155/2016/8191254
  7. Tamayo E., Gómez E., Bustamante J., et al. Evolution of neutrophil apoptosis in septic shock survivors and nonsurvivors. J Critical Care. 2012; 27: 415. e1–415.e11. DOI: 10.1016/j.jcrc.2011.09.001
  8. Camicia G., Pozner R., de Larran G. Neutrophil extracellular traps in sepsis. Shock. 2014; 42(4): 286–94. DOI: 10.1097/SHK.0000000000000221
  9. Law Sh. M., Gray R.D. Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease: a review. J Inflamm (Lond). 2017; 14: 29. DOI: 10.1186/s12950-017-0176-1
  10. Зубкова Ж.В., Новикова И.А., Железко В.В. Влияние тромбоцитов на формирование нейтрофилами экстрацеллюлярных сетей у пациентов с иммунокомпслексной патологией. Проблемы здоровья иэкологии. 2016; 3(49): 66–70. [Zubkova Zh.V., Novikova I.A., Zhelezko V.V. Influence of platelets on the formation of extracellular networks by neutrophils in patients with immunocompslex pathology. Problems of health and ecology. 2016; 3(49): 66–70. (In Russ)]
  11. Li T., Wang C., Liu Y., et al. Neutrophil extracellular traps induce intestinal damage and thrombotic tendency in inflammatory bowel disease. J Crohns Colitis. 2020; 10;14(2):240-253. DOI: 10.1093/ecco-jcc/jjz132.
  12. Moschonas I.C., Tselepis A.D. The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis. Atherosclerosis. 2019;288:9-16. DOI: 10.1016/j.atherosclerosis.2019.06.919.
  13. Yalavarthi S., Gould T.J., Rao A.N., et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies. A newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis & Rheumatology. 2015;67(11): 2990-3003. DOI:10.1002/art.39247
  14. Bravo-Barrera J., Kourilovitch M., Galarza-Maldonado C. Neutrophil extracellular traps, antiphospholipid antibodies and treatment. Antibodies. 2017; 6: 4; DOI:10.3390/antib6010004
  15. Gardiner Ch., Vatish M. Impact of haemostatic mechanisms on pathophysiology of preeclampsia. Thrombosis Research. 2017; 151(1): 48–52. DOI: 10.1016/S0049-3848(17)30067-1
  16. Goulopoulou S., Davidge S.T. Molecular mechanisms of maternal vascular dysfunction in preeclampsia. Trends Mol Med. 2015; 21(2): 88–97. DOI: 10.1016/j.molmed.2014.11.009
  17. Ratsep M.T., Felker A.M., Kay V.R., et al. Uterine natural killer cells: supervisors of vasculature construction in early decidua basalis. Reproduction. 2015; 49: 91–102. DOI: 10.1530/REP-14-0271
  18. Chaiworapongsa T., Chaemsaithong P., Yeo L., et al. Pre-eclampsia part 1: current understanding of its pathophysiology. Perinatology Nat Rev Nephrol. 2014; 10(8): 466–80. DOI: 10.1038/nrneph.2014.102
  19. Giaglisa S., Stoikoua M., Grimolizzia F., et al. Neutrophil migration into the placenta: Good, bad or deadly? Cell Adhesion & Migration. 2016; 10(1–2): 1–18. DOI: 10.1080/19336918.2016.1148866
  20. Gupta A.K., Hasler P., Holzgreve W., et al. Induction of Neutrophil Extracellular DNA Lattices by Placental Microparticles and IL-8 and Their Presence in Preeclampsia. Human Immunology. 2005: (66): 1146–54. DOI: 10.1016/j.humimm.2005.11.003
  21. Gupta A., Hasler P., Gebhardt S., et al. Occurrence of Neutrophil Extracellular DNA Traps (NETs) in Pre-Eclampsia A Link with Elevated Levels of Cell-Free DNA? Ann. N.Y. Acad. Sci. 2006; (1075): 118–22. DOI: 10.1196/annals.1368.015
  22. Germain S.J., Sacks G.P., Soorana S.R., et al. Systemic Inflammatory Priming in Normal Pregnancy and Preeclampsia: The Role of Circulating Syncytiotrophoblast Microparticles. J Immunol. 2007; (178): 5949–56. DOI: 10.4049/jimmunol.178.9.5949
  23. НестероваИ.В., Колесникова Н.В., Чудилова Г.А. и др. Нейтрофильные гранулоциты: новый взгляд на «старых игроков» на иммунологическом поле. Иммунология. 2015; 36(4): 257–64. [Nesterova I.V., Kolesnikova N.V., Chudilova G.A., et al. Neutrophil granulocytes: a new look at the «old players» in the immunological field. Immunologiya. 2015; 36(4): 257–65. (In Russ)]
  24. Степанова Р.Н. Преэклампсия, эклампсия: терминология и классификация. Ульяновский медико-биологический журнал. 2018; 2:41-46. [Stepanova R.N. Preeclampsia, eclampsia: terminology and classification. Ulyanovsk Medical and Biological Journal. 2018; 2:41-46. (In Russ)]. DOI:10.23648/UMBJ.2018.30.13994
  25. ЖуковаА.П., Травин М.А., Залавина С.В. и др. Наблюдение материнской смертности при преждевременной отслойке плаценты. Вестник судебной медицины. 2018; 1(7): 31–4. [Zhukova A.P., Travin M.A., Zalavina S.V., et al. Observation of maternal mortality in premature placental abruption. Bulletin of Forensic Medicine. 2018; 1(7): 31–4. (In Russ)]
  26. Петров Ю.А., Купина А.Д. Преэклампсия и эклампсия: перспективные возможности диагностики и профилактики. Мать идитя в Кузбассе. 2020; 2(81): 54–60. [Petrov Yu.A., Kupina A.D. Preeclampsia and eclampsia: promising opportunities for diagnosis and prevention. Mother and child in Kuzbass. 2020; 2(81): 54–60. DOI: 10.24411/2686–7338 -2020-10023 (In Russ)]
  27. ИбрагимоваС.М., Стрижаков А.Н., Тимохина Е.В. и др. Особенности течения Hellp-синдрома. Материалы 2-й международной конференции «Гемостаз, тромбоз и репродукция: междисциплинарный подход». Акушерство и гинекология Санкт-Петербурга. 2018; (2): 8–8а. [Ibragimova S.M., Strizhakov A.N., Timokhina E.V., et al. Features of the course of Hellp syndrome. Materials of the All-Russian Conference with international participation «Hemostasis, thrombosis and reproduction: an interdisciplinary approach». Obstetrics and Gynaecology of Saint-Petersburg. 2018; (2): 8–8а. (In Russ)]
  28. СюндюковаЕ.Г., Чулков В.С., Рябикина М.Г. Преэклампсия: современное состояние проблемы. Доктор.Ру. 2021; 20(1): 11–6. [Syundyukova E.G., Chulkov V.S., Ryabikina M.G. Preeclampsia: the current state of the problem. Ru. 2021; 20(1): 11–6. DOI: 10.31550/1727-2378-2021-20-1-11-16 (In Russ)]
  29. Ющенко М.И., Дука Ю.М. Роль своевременного определения соотношения PIGF⁄ sFlt-1 как раннего маркера преэклампсии. Акушерство и гинекология Санкт-Петербурга. 2019; 2: 41. [Yushchenko M.I., Duka Y.M. The role of timely determination of the ratio of PIGF ⁄ sFlt-1 as an early marker of preeclampsia. Obstetrics and gynecology of St. Petersburg. 2019; 2: 41. (In Russ)]
  30. Lim С.C.Y., Patel D.K., Bakhtiari A., et al. An unusual presentation of gestational thrombocytopenia. Platelets. 2013; 24(6): 498–9. DOI: 10.3109/09537104.2012.724484
  31. Win N., Rowley M., Pollard C., et al. Severe gestational (incidental) thrombocytopenia: To treat or not to treat. Hematology. 2005; 10(1): 69–72. DOI: 10.1080/10245330400020421
  32. Лихванцев В.В., Ядгаров М.Я., Берикашвили Л.Б. и др. Определение объема выборки. Анестезиология и реаниматология. 2020; 6: 77-86. [Likhvantsev VV, Yadgarov MYa, Berikashvili LB, Kadantseva KK, Kuzovlev AN. Sample size estimation. Russian Journal of Anaesthesiology and Reanimatology. 2020; 6: 77-86. (In Russ)] DOI:10.17116/anaesthesiology202006177
  33. Гипертензивные расстройства во время беременности, родах и послеродовом периоде. Преэклампсия. Эклампсия. Клинические рекомендации (Протоколы лечения). 2016. Дата доступа 15 октября 2021. Режим доступа: https://mz.mosreg.ru/upload/iblock/fcc/gipertenzivnye-rasstroystva-vo-vremya-beremennosti_-v-rodakh-i-poslerodovom-periode.-preeklampsiya.-eklampsiya.pdf [Gipertenzivnye rasstrojstva vo vremya beremennosti, rodah i poslerodovom periode. Eklampsiya. Klinicheskie rekomendacii (Protokoly lecheniya). 2016. Accessed 2021 Oct 15. Available from: https://mz.mosreg.ru/upload/iblock/fcc/gipertenzivnye-rasstroystva-vo-vremya-beremennosti_-v-rodakh-i-poslerodovom-periode.-preeklampsiya.-eklampsiya.pdf (In Russ)]
  34. Войцеховский В.В., Заболотских Т.В., Целуйко С.С. Тромбоцитопении. Амурский медицинский журнал. 2017: 18(2): 7–25. [Voytsekhovsky V.V., Zabolotskih T.V., Tseluyko S.S. Thrombocytopenia. Amur Medical Journal. 2017; 18(2): 7–25. (In Russ)]
  35. Rana S., Lemoine E., Granger J.P., et al. Preeclampsia Pathophysiology, Challenges, and Perspectives Circ Res. 2019; 124: 1094–112. DOI: 10.1161/CIRCRESAHA.118.313276
  36. Phipps E.A., Thadhani R., Benzing Th., et al. Pre-eclampsia: pathogenesis, novel diagnostics and therapiesNature reviews. Nat Rev Nephrol. 2019; 15(5): 275–89. DOI: 10.1038/ s41581-019-0119-6
  37. Sutton A.L.M., Harper L.M., Tita A.T.N. Hypertensive Disorders in Pregnanc. Obstet Gynecol Clin North Am. 2018; 45(2): 333–47. DOI: 10.1016/j.ogc.2018.01.012
  38. Saffarzadeh M., Juenemann Ch., Queisser M.A., et al. Neutrophil Extracellular Traps Directly Induce Epithelial and Endothelial Cell Death: A Predominant Role of Histones. PLoS One. 2012; 7(2): e32366. DOI: 10.1371/journal.pone.0032366
  39. Fuchsa T.A., Brilla A., Duerschmieda D., et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 2010; 107(36): 15880–5. DOI: 10.1073/pnas.1005743107
  40. БицадзеВ.О., Слуханчук Е.В., Хизроева Д.Х. и др. Внеклеточные ловушки нейтрофилов (NETS) в патогенезе тромбоза и тромбовоспалительных заболеваний. Вестник российской академии медицинских наук. 2021; 76 (1): 75–85. [Bitsadze V.O., Slushanchuk E.V., Khizroeva D.H., et al. Extracellular neutrophil traps (NETS) in the pathogenesis of thrombosis and thrombi of inflammatory diseases. Bulletin of the Russian Academy of Medical Sciences. 2021; 76 (1): 75–85. DOI: 10.15690/vramn1395 (In Russ)]